This is a working overview of adipose tissue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-20 and is reviewed periodically as new material appears.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Relationship with other guerrillas === The Hukhbalahap's methods were generally terrorist in nature; for example, Ray Hunt, an American who led his own band of 3,000 guerrillas, said of the Hukbalahap that
== Biological roles == Retinol or other forms of vitamin A are needed for eyesight, maintenance of the skin, and human development. Other than for vision, which requires 11-cis retinal, the active compound is retinoic acid, synthesized from retinal, in turn synthesized from retinol. The differing biological roles of retinoic acid depend on its stereochemistry and whether it is present in the all-trans, 9-cis, or 13-cis forms.
The calling in question of the actions and policies of government led to a new climate of debate. The issues of emancipation, colonialism, environmentalism and grassroots democracy were discussed at all levels of society. In 1979, the environmental party, the Greens, reached the 5% limit required to obtain parliamentary seats in the Free Hanseatic City of Bremen provincial election. Also of great significance was the steady growth of a feminist movement in which women demonstrated for equal rights. Until 1977, a married woman had to have the permission of her husband if she wanted to take on a job or open a bank account. Further reforms in 1979 to parental rights law gave equal legal rights to the mother and the father, abolishing the legal authority of the father. Parallel to this, a gay movement began to grow in the larger cities, especially in West Berlin, where homosexuality had been widely accepted during the twenties in the Weimar Republic.
==== MeSH D12.776.575.750.500 – mitochondrial adp, atp translocases ==== MeSH D12.776.575.750.500.100 – adenine nucleotide translocator 1 MeSH D12.776.575.750.500.200 – adenine nucleotide translocator 2 MeSH D12.776.575.750.500.300 – adenine nucleotide translocator 3
Sources: en.wikipedia.org
=== Bibliography === I Can't Make This Up: Life Lessons (2017) The Decision: Overcoming Today's BS for Tomorrow's Success (2020) Marcus Makes a Movie (2021) Marcus Makes It Big (2022) Monsters and How to Tame Them: Taking Charge of the Voices in Your Head (2022)
People with early keratoconus often notice a minor blurring or distortion of their vision, as well as an increased sensitivity to light, so they may visit their clinician seeking corrective lenses for reading or driving. At early stages, the symptoms of keratoconus may be no different from those of any other refractive defect of the eye. As the disease progresses, vision deteriorates, sometimes rapidly due to irregular astigmatism. Visual acuity becomes impaired at all distances, and night vision is often poor. Some individuals have vision in one eye that is markedly worse than the other eye. The disease is often bilateral though asymmetrical. Some develop photophobia (sensitivity to bright light), eye strain from squinting in order to read, or itching in the eye, but there is normally little or no sensation of pain. It may cause luminous objects to appear as cylindrical pipes with the same intensity at all points.
==== MeSH D08.811.600 – multienzyme complexes ==== MeSH D08.811.600.075 – anthranilate phosphoribosyltransferase MeSH D08.811.600.085 – anthranilate synthase MeSH D08.811.600.116 – aspartate carbamoyltransferase MeSH D08.811.600.130 – aspartokinase homoserine dehydrogenase MeSH D08.811.600.200 – cholesterol side-chain cleavage enzyme MeSH D08.811.600.250 – electron transport chain complex proteins MeSH D08.811.600.250.500 – electron-transferring flavoproteins MeSH D08.811.600.250.500.500 – electron transport complex i MeSH D08.811.600.250.500.750 – electron transport complex ii MeSH D08.811.600.250.500.750.500 – succinate dehydrogenase MeSH D08.811.600.250.687 – electron transport complex iv MeSH D08.811.600.250.875 – succinate cytochrome c oxidoreductase MeSH D08.811.600.250.875.249 – electron transport complex ii MeSH D08.811.600.250.875.249.500 – succinate dehydrogenase MeSH D08.811.600.250.875.500 – electron transport complex iii MeSH D08.811.600.317 – fatty acid synthetase complex MeSH D08.811.600.391 – glycine decarboxylase complex MeSH D08.811.600.391.100 – aminomethyltransferase MeSH D08.811.600.391.150 – dihydrolipoamide dehydrogenase MeSH D08.811.600.391.175 – glycine decarboxylase complex h-protein MeSH D08.811.600.391.200 – glycine dehydrogenase (decarboxylating) MeSH D08.811.600.465 – ketoglutarate dehydrogenase complex MeSH D08.811.600.465.500 – dihydrolipoamide dehydrogenase MeSH D08.811.600.541 – lactose synthase MeSH D08.811.600.700 – phosphoenolpyruvate sugar phosphotransferase system MeSH D08.811.600.710 – photosynthetic reaction center complex proteins MeSH D08.811.600.710.249 – light-harvesting protein complexes MeSH D08.811.600.710.374 – cytochrome b6f complex MeSH D08.811.600.710.374.500 – cytochromes b6 MeSH D08.811.600.710.374.750 – cytochromes f MeSH D08.811.600.710.374.875 – plastoquinol-plastocyanin reductase MeSH D08.811.600.710.500 – photosystem i protein complex MeSH D08.811.600.710.750 – photosystem ii protein complex MeSH D08.811.600.715 – polyketide synthases MeSH D08.811.600.720 – prostaglandin-endoperoxide synthases MeSH D08.811.600.720.500 – cyclooxygenase 1 MeSH D08.811.600.720.750 – cyclooxygenase 2 MeSH D08.811.600.730 – proteasome endopeptidase complex MeSH D08.811.600.741 – pyruvate dehydrogenase complex MeSH D08.811.600.741.525 – dihydrolipoamide dehydrogenase MeSH D08.811.600.741.625 – dihydrolipoyllysine-residue acetyltransferase MeSH D08.811.600.741.725 – pyruvate dehydrogenase (lipoamide) MeSH D08.811.600.850 – sucrase-isomaltase complex MeSH D08.811.600.896 – tryptophan synthase
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.